Welcome to our dedicated page for Pheton Holdings SEC filings (Ticker: PTHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Pheton Holdings Ltd (PTHL), a Cayman Islands healthcare solution provider focused on treatment planning systems for brachytherapy and related products and services. As a foreign private issuer, the company files an annual report on Form 20-F and furnishes current reports on Form 6-K to disclose financial information and material corporate events.
Through Pheton’s SEC filings, readers can review unaudited interim condensed consolidated financial statements, which have been furnished on Form 6-K for specified periods. These filings include financial statements and accompanying notes, as well as Inline XBRL data files that structure key financial information for analysis.
The company’s 6-K reports also document corporate governance and organizational changes, such as the appointment and resignation of independent directors, the engagement of an independent registered public accounting firm, and the furnishing of notices and proxy statements for its annual general meeting of shareholders. Certain filings include updated memorandum and articles of association, reflecting changes associated with the corporate name iTonic Holdings Ltd.
Investors can find details on capital markets and transaction activity in Pheton’s filings. The company has reported its initial public offering on the Nasdaq Capital Market, advisory services agreements related to mergers and acquisitions strategies, and stock purchase agreements to acquire equity interests in healthcare technology targets, including iTonic Corporation and a company established to develop and commercialize advanced medical device technologies. These reports describe consideration structures involving newly issued Class A ordinary shares and warrants, as well as regulatory exemptions relied upon for unregistered sales of securities.
Filings further disclose Nasdaq listing compliance matters, including a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the minimum bid price requirement and the associated compliance period. In addition, a current report describes Pheton’s plan to change its corporate name to iTonic Holdings Ltd and its Nasdaq ticker symbol from "PTHL" to "ITOC," explaining that these changes reflect a new business strategy and future development plans.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR, and AI-powered tools can help summarize lengthy filings such as Form 20-F annual reports or detailed Form 6-K exhibits. Users can quickly identify key points about Pheton’s financial condition, acquisitions, governance changes, and listing status, and can also review disclosures related to equity issuances and warrant arrangements. For those researching the historical PTHL ticker and the transition to ITOC, this filings archive offers a structured view of how the company’s regulatory record has developed over time.
Pheton Holdings Ltd entered into a stock purchase agreement to acquire 51% of the outstanding shares of iTonic Corporation, a provider of a home health platform that integrates medication dispensing, supply chain management, virtual care, and patient monitoring. As consideration, Pheton agreed to issue 4,000,000 newly issued Class A ordinary shares and warrants to purchase up to 3,000,000 Class A ordinary shares to the selling shareholders.
The consideration shares will be locked up and released only if iTonic meets agreed performance milestones tied to sales volume and sales revenue, measured quarterly beginning January 1, 2026. The warrants are also subject to milestone-based exercisability. The transaction is subject to customary closing conditions and may not close if those conditions are not satisfied.
The consideration shares, the warrants, and the Class A ordinary shares issuable upon warrant exercise will be issued in a private placement, relying on exemptions from registration under Section 4(a)(2) and Rule 506(b) of Regulation D and Regulation S for offers and sales outside the U.S.